Ovine pulmonary adenocarcinoma (OPA) can be reproduced consistently in neonatal lambs by intratracheal injection of inocula containing jaagsiekte sheep retrovirus (JSRV). In this study, clinical disease, confirmed pathologically as OPA, was induced in a high proportion of lambs that had been inoculated intratracheally with infectious lung fluid at 1, 3 and 6 months of age. The incubation periods, however, were longer in these three age groups than in 1-week-old lambs that were used as controls. Viraemia was detected in all age groups before onset of clinical signs, but occurred later in older animals. These results suggest an age-dependent susceptibility to OPA that could be determined by the availability of JSRV target cells in the ovine lung. The feasibility of inducing OPA in older lambs and detecting JSRV viraemia in preclinical stages enables improved studies on the pathogenesis, assessment of vaccines, diagnosis and control of the disease.
Summary
An outbreak of enzootic intranasal tumour (EIT) in a goat herd in Central Italy is described. From October 1990 to September 1992 41 tumors were diagnosed in goats ranging in age from 6 months to 6 years and of both the Alpine and Saanen breeds. Clinically the affected goats showed nasal discharge, facial swelling, sneezing and snoring respiration and weight loss.
Post‐mortem examinations revealed uni‐ or bilateral tumours of the olfactory mucous membrane. The neoplasms were classified as low grade adenocarcinomas. Ultrastructurally, retrovirus‐like particles were observed in 10/10 tumours examined.
Epidemiological and ultrastructural findings strongly suggest a viral aetiology for intranasal enzootic adenocarcinoma in the goats examined.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.